Danaher Corporation $DHR Stock Holdings Lifted by Elmwood Wealth Management Inc.

Posted by Brian Himes on Oct 14th, 2026

Elmwood Wealth Management Inc. lifted its stake in Danaher Corporation (NYSE:DHR – Free Report) by 73.2% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 9,986 shares of the conglomerate’s stock after acquiring an additional 4,222 shares during the quarter. Elmwood Wealth Management Inc.’s holdings in Danaher were worth $2,212,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of DHR. BlackRock Inc. purchased a new stake in shares of Danaher during the 2nd quarter valued at about $10,492,520,000. Jupiter Topco LLC acquired a new position in shares of Danaher during the second quarter worth $1,456,317,000. Generation Investment Management LLP acquired a new position in shares of Danaher during the second quarter worth $1,287,949,000. Bank of America Corp DE purchased a new position in shares of Danaher in the second quarter valued at $993,846,000. Finally, Legal & General Group Plc purchased a new position in shares of Danaher in the second quarter valued at $801,056,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Up 0.8%

Shares of DHR stock traded up $1.81 during mid-day trading on Wednesday, reaching $224.65. 3,595,884 shares of the company were exchanged, compared to its average volume of 4,457,645. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. The business’s 50 day simple moving average is $212.41 and its 200 day simple moving average is $195.13. The company has a market capitalization of $157.93 billion, a P/E ratio of 39.90, a P/E/G ratio of 2.78 and a beta of 0.76. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80.

Danaher (NYSE:DHR – Get Free Report) last posted its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The firm had revenue of $6.26 billion for the quarter, compared to analysts’ expectations of $6.12 billion. During the same period in the prior year, the company posted $0.77 earnings per share. The firm’s quarterly revenue was up 5.5% on a year-over-year basis. Research analysts predict that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.40 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. Danaher’s payout ratio is presently 28.42%.

Danaher News Summary

Here are the key news stories impacting Danaher this week:

Positive Sentiment: Potential earnings beat: Zacks says Danaher has a strong earnings-surprise history and currently shows the two indicators—earnings estimate revisions and an Earnings ESP reading—that can signal another quarterly beat. Analysts expect earnings growth in the upcoming report. Will Danaher Beat Estimates Again in Its Next Earnings Report?
Positive Sentiment: NVIDIA collaboration supports AI strategy: Danaher announced a partnership with NVIDIA to combine its scientific instruments, laboratory automation, workflow software and domain expertise with NVIDIA’s accelerated computing and AI technologies. The goal is to advance autonomous science and speed up scientific discovery, creating a potentially important long-term growth opportunity in life-science research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
Positive Sentiment: Autonomous laboratory plans: Danaher plans to launch its first AI-powered autonomous laboratory, with commercial-scale operations expected in early 2027. The initiative could improve laboratory productivity and strengthen Danaher’s positioning in AI-enabled drug discovery, though meaningful revenue benefits are likely longer term. How to Invest in AI Drug Discovery
Neutral Sentiment: Analyst support: Morgan Stanley maintained its $240 price target for DHR, indicating continued confidence in the company’s outlook but no new change in the valuation view. Morgan Stanley Keeps $240 Target for Danaher Stock
Neutral Sentiment: Board expansion: Danaher expanded its board to 13 members and appointed new directors, a governance development with limited immediate earnings impact. Danaher Enhances Board With New Director Appointments

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on DHR. Weiss Ratings raised shares of Danaher from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, September 16th. Royal Bank Of Canada boosted their price objective on shares of Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a report on Monday, October 5th. TD Cowen boosted their price objective on shares of Danaher from $236.00 to $255.00 and gave the stock a “buy” rating in a report on Tuesday. Wells Fargo & Company decreased their price objective on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 22nd. Finally, Morgan Stanley raised their target price on Danaher from $220.00 to $240.00 and gave the company an “overweight” rating in a research note on Monday. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $235.41.

Read Our Latest Stock Analysis on DHR

Danaher Profile

(Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.